Anna is currently a Medical Director in gene therapy at Pfizer. In this role, Anna is responsible for medical strategy for a Duchenne Muscular Dystrophy gene therapy that is currently in clinical trials, and focuses on value, real world evidence and access. Anna has been in medical affairs for over eight years, including previous roles at Bristol Myers Squibb and Alcon, where she brought her neuroscience and research expertise to drive scientific publications and content.

Anna holds a PhD in Neuroscience (Johns Hopkins University) and a Bachelors in Molecular and Cellular Biology (Vanderbilt University), where she conducted ten years of neuroscience research in various animal models, and taught 16 courses in biological subjects.